Mitoxantrone therapy in multiple sclerosis and acute leukaemia: A case report out of 644 treated patients

Multiple Sclerosis

Volumn 10, Issue 4, 2004, Pages 472-474

  Voltz, Raymond ^a   Starck, Michaela ^b   Zingler, Vera ^a   Strupp, Michael ^a   Kolb, Hans Jochem ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Multiple Sklerose Klinik   (Germany)

Author keywords

Leukaemia; Mitoxantrone; Multiple sclerosis

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER RECURRENCE; CASE REPORT; CHROMOSOME 11; CHROMOSOME 16; CHROMOSOME INVERSION; DISEASE EXACERBATION; DOSE RESPONSE; FEMALE; FREQUENCY ANALYSIS; HUMAN; MULTIPLE SCLEROSIS; PARTIAL TRISOMY; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 16; DNA TOPOISOMERASES, TYPE I; FEMALE; HUMANS; INVERSION, CHROMOSOME; LEUKEMIA, MYELOCYTIC, ACUTE; MIDDLE AGED; MITOXANTRONE; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; SEVERITY OF ILLNESS INDEX; TRANSPLANTATION, HOMOLOGOUS; TRISOMY;

EID: 4344569251     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458504ms1047cr     Document Type: Article

References (14)

1. Pedersen-Bjergaard J, Philip P. Two different classes of therapy-related and de-novo acute myeloid leukemia? Cancer Genet Cytogenet 1991; 55: 119-24.
2. Felix CA. Secondary leukemias induced by topoisomerase-targeted drugs. Biochim Biophys Acta 1998; 1400: 233-55.
3. Linassier C, Barin C, Calais G, Letortorec S, Bremond JL, Delain M et al. Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy. Ann Oncol 2000; 11: 1289-94.
4. Hartung HP, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey SP et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360: 2018-25.
5. Vicari AM, Ciceri F, Folli F, Lanzi R, Colombo B, Comi G et al. Acute promyelocytic leukemia following mitoxantrone as single agent for the treatment of multiple sclerosis. Leukemia 1998; 12: 441-42.
6. Radu TD, Marc D, Herve V. Acute myeloid leukaemia (AML) induced by mitoxantrone. Mult Scler 2002; 8: P342, S127.
7. Ghalie RG, Mauch E, Edan G, Hartung HP, Gonsette RE, Eisenmann S et al. A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler 2002; 8: 441-45.
8. Heesen C, Bruegmann M, Gbdamosi J, Koch E, Monch A, Buhmann C. Therapy-related acute myelogenous leukaemia (t-AML) in a patient with multiple sclerosis treated with mitoxantrone. Mult Scler 2003; 9: 213-14.
9. Brassat D, Recher C, Waubant E, Le Page E, Rigal-Huguet F, Laurent G et al. Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS. Neurology 2002; 59: 954-55.
10. Cattaneo C, Almici C, Borlenghi E, Motta M, Rossi G. A case of acute promyelocytic leukaemia following mitoxantrone treatment of multiple sclerosis. Leukemia 2003; 17: 985-86.
11. Goodkin DE. Therapy-related leukaemia in mitoxantrone treated patients. Mult Scler 2003; 9: 426.
12. Delisse B, de Seze J, Mackowiak A, N'Kendjuo JB, Verier A, Derepeer O et al. Therapy related acute myeloblastic leukaemia after mitoxantrone treatment in a patient with multiple sclerosis. Mult Scler 2004; 10: 92.
13. Greer JP, Foerster J, Lukens JN, Rodgers GM, Paraskevas F, Clader BE eds. Wintrobe's clinical hematology, eleventh edition. Philadelphia, PA: Lippincott Williams & Wilkins, 2003.
14. Martinez-Climent JA, Comes AM, Vizcarra E, Reshmi S, Benet I, Marugan I et al. Variant three-way translocation of inversion 16 in AML-M4Eo confirmed by fluorescence in situ hybridization analysis. Cancer Genet Cytogenet 1999; 110: 111-14.